false P3Y P5Y 0.010000 2020 Q3--02-29 Yes Yes NEOGEN CORP 0000711377 Large Accelerated Filer true false MI MI Excluding the nine months ended February 29, 2020. Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions.Includes elimination of intersegment transactions. 0000711377 2019-06-01 2020-02-29 0000711377 2020-02-29 0000711377 2019-05-31 0000711377 2019-12-01 2020-02-29 0000711377 2018-12-01 2019-02-28 0000711377 2018-06-01 2019-02-28 0000711377 2019-11-30 0000711377 2018-10-31 0000711377 2018-12-31 0000711377 2018-11-01 2018-11-29 0000711377 2019-06-01 0000711377 2018-12-01 2018-12-31 0000711377 2019-06-01 2019-08-31 0000711377 2018-09-01 2018-11-30 0000711377 2018-06-01 2018-08-31 0000711377 2019-09-01 2019-11-30 0000711377 2019-02-28 0000711377 2018-05-31 0000711377 2019-08-31 0000711377 2018-08-31 0000711377 2018-11-30 0000711377 neog:FoodSafetyMember us-gaap:OperatingSegmentsMember 2020-02-29 0000711377 neog:AnimalSafetyMember us-gaap:OperatingSegmentsMember 2020-02-29 0000711377 us-gaap:IntersubsegmentEliminationsMember us-gaap:OperatingSegmentsMember 2020-02-29 0000711377 neog:FoodSafetyMember 2019-12-01 2020-02-29 0000711377 neog:AnimalSafetyMember 2019-12-01 2020-02-29 0000711377 neog:NaturalToxinsAllergensAndDrugResiduesMember neog:FoodSafetyMember 2019-12-01 2020-02-29 0000711377 neog:BacterialAndGeneralSanitationMember neog:FoodSafetyMember 2019-12-01 2020-02-29 0000711377 neog:CultureMediaAndOtherMember neog:FoodSafetyMember 2019-12-01 2020-02-29 0000711377 neog:RodenticidesInsecticidesAndDisinfectantsMember neog:FoodSafetyMember 2019-12-01 2020-02-29 0000711377 neog:GenomicsServicesMember neog:FoodSafetyMember 2019-12-01 2020-02-29 0000711377 neog:LifeSciencesMember neog:AnimalSafetyMember 2019-12-01 2020-02-29 0000711377 neog:VeterinaryInstrumentsAndDisposablesMember neog:AnimalSafetyMember 2019-12-01 2020-02-29 0000711377 neog:AnimalCareAndOtherMember neog:AnimalSafetyMember 2019-12-01 2020-02-29 0000711377 neog:RodenticidesInsecticidesAndDisinfectantsMember neog:AnimalSafetyMember 2019-12-01 2020-02-29 0000711377 neog:GenomicsServicesMember neog:AnimalSafetyMember 2019-12-01 2020-02-29 0000711377 country:US 2019-12-01 2020-02-29 0000711377 us-gaap:NonUsMember 2019-12-01 2020-02-29 0000711377 us-gaap:ProductMember neog:FoodSafetyMember us-gaap:OperatingSegmentsMember 2019-12-01 2020-02-29 0000711377 us-gaap:ProductMember neog:AnimalSafetyMember us-gaap:OperatingSegmentsMember 2019-12-01 2020-02-29 0000711377 us-gaap:ProductMember 2019-12-01 2020-02-29 0000711377 us-gaap:ServiceMember neog:FoodSafetyMember us-gaap:OperatingSegmentsMember 2019-12-01 2020-02-29 0000711377 us-gaap:ServiceMember neog:AnimalSafetyMember us-gaap:OperatingSegmentsMember 2019-12-01 2020-02-29 0000711377 us-gaap:ServiceMember 2019-12-01 2020-02-29 0000711377 neog:FoodSafetyMember us-gaap:OperatingSegmentsMember 2019-12-01 2020-02-29 0000711377 neog:AnimalSafetyMember us-gaap:OperatingSegmentsMember 2019-12-01 2020-02-29 0000711377 us-gaap:IntersubsegmentEliminationsMember us-gaap:OperatingSegmentsMember 2019-12-01 2020-02-29 0000711377 us-gaap:CommonStockMember 2019-12-01 2020-02-29 0000711377 us-gaap:AdditionalPaidInCapitalMember 2019-12-01 2020-02-29 0000711377 us-gaap:RetainedEarningsMember 2019-12-01 2020-02-29 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-01 2020-02-29 0000711377 neog:FoodSafetyMember 2018-12-01 2019-02-28 0000711377 neog:AnimalSafetyMember 2018-12-01 2019-02-28 0000711377 neog:NaturalToxinsAllergensAndDrugResiduesMember neog:FoodSafetyMember 2018-12-01 2019-02-28 0000711377 neog:BacterialAndGeneralSanitationMember neog:FoodSafetyMember 2018-12-01 2019-02-28 0000711377 neog:CultureMediaAndOtherMember neog:FoodSafetyMember 2018-12-01 2019-02-28 0000711377 neog:RodenticidesInsecticidesAndDisinfectantsMember neog:FoodSafetyMember 2018-12-01 2019-02-28 0000711377 neog:GenomicsServicesMember neog:FoodSafetyMember 2018-12-01 2019-02-28 0000711377 neog:LifeSciencesMember neog:AnimalSafetyMember 2018-12-01 2019-02-28 0000711377 neog:VeterinaryInstrumentsAndDisposablesMember neog:AnimalSafetyMember 2018-12-01 2019-02-28 0000711377 neog:AnimalCareAndOtherMember neog:AnimalSafetyMember 2018-12-01 2019-02-28 0000711377 neog:RodenticidesInsecticidesAndDisinfectantsMember neog:AnimalSafetyMember 2018-12-01 2019-02-28 0000711377 neog:GenomicsServicesMember neog:AnimalSafetyMember 2018-12-01 2019-02-28 0000711377 country:US 2018-12-01 2019-02-28 0000711377 us-gaap:NonUsMember 2018-12-01 2019-02-28 0000711377 us-gaap:ProductMember neog:FoodSafetyMember us-gaap:OperatingSegmentsMember 2018-12-01 2019-02-28 0000711377 us-gaap:ProductMember neog:AnimalSafetyMember us-gaap:OperatingSegmentsMember 2018-12-01 2019-02-28 0000711377 us-gaap:ProductMember 2018-12-01 2019-02-28 0000711377 us-gaap:ServiceMember neog:FoodSafetyMember us-gaap:OperatingSegmentsMember 2018-12-01 2019-02-28 0000711377 us-gaap:ServiceMember neog:AnimalSafetyMember us-gaap:OperatingSegmentsMember 2018-12-01 2019-02-28 0000711377 us-gaap:ServiceMember 2018-12-01 2019-02-28 0000711377 neog:FoodSafetyMember us-gaap:OperatingSegmentsMember 2018-12-01 2019-02-28 0000711377 neog:AnimalSafetyMember us-gaap:OperatingSegmentsMember 2018-12-01 2019-02-28 0000711377 us-gaap:IntersubsegmentEliminationsMember us-gaap:OperatingSegmentsMember 2018-12-01 2019-02-28 0000711377 us-gaap:CommonStockMember 2018-12-01 2019-02-28 0000711377 us-gaap:AdditionalPaidInCapitalMember 2018-12-01 2019-02-28 0000711377 us-gaap:RetainedEarningsMember 2018-12-01 2019-02-28 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-01 2019-02-28 0000711377 srt:MinimumMember 2019-06-01 2020-02-29 0000711377 srt:MaximumMember 2019-06-01 2020-02-29 0000711377 neog:FoodSafetyMember 2019-06-01 2020-02-29 0000711377 neog:AnimalSafetyMember 2019-06-01 2020-02-29 0000711377 neog:NaturalToxinsAllergensAndDrugResiduesMember neog:FoodSafetyMember 2019-06-01 2020-02-29 0000711377 neog:BacterialAndGeneralSanitationMember neog:FoodSafetyMember 2019-06-01 2020-02-29 0000711377 neog:CultureMediaAndOtherMember neog:FoodSafetyMember 2019-06-01 2020-02-29 0000711377 neog:RodenticidesInsecticidesAndDisinfectantsMember neog:FoodSafetyMember 2019-06-01 2020-02-29 0000711377 neog:GenomicsServicesMember neog:FoodSafetyMember 2019-06-01 2020-02-29 0000711377 neog:LifeSciencesMember neog:AnimalSafetyMember 2019-06-01 2020-02-29 0000711377 neog:VeterinaryInstrumentsAndDisposablesMember neog:AnimalSafetyMember 2019-06-01 2020-02-29 0000711377 neog:AnimalCareAndOtherMember neog:AnimalSafetyMember 2019-06-01 2020-02-29 0000711377 neog:RodenticidesInsecticidesAndDisinfectantsMember neog:AnimalSafetyMember 2019-06-01 2020-02-29 0000711377 neog:GenomicsServicesMember neog:AnimalSafetyMember 2019-06-01 2020-02-29 0000711377 us-gaap:NonUsMember 2019-06-01 2020-02-29 0000711377 country:US 2019-06-01 2020-02-29 0000711377 us-gaap:ProductMember 2019-06-01 2020-02-29 0000711377 us-gaap:ProductMember neog:FoodSafetyMember us-gaap:OperatingSegmentsMember 2019-06-01 2020-02-29 0000711377 us-gaap:ProductMember neog:AnimalSafetyMember us-gaap:OperatingSegmentsMember 2019-06-01 2020-02-29 0000711377 us-gaap:ServiceMember neog:FoodSafetyMember us-gaap:OperatingSegmentsMember 2019-06-01 2020-02-29 0000711377 us-gaap:ServiceMember neog:AnimalSafetyMember us-gaap:OperatingSegmentsMember 2019-06-01 2020-02-29 0000711377 us-gaap:ServiceMember 2019-06-01 2020-02-29 0000711377 neog:FoodSafetyMember us-gaap:OperatingSegmentsMember 2019-06-01 2020-02-29 0000711377 neog:AnimalSafetyMember us-gaap:OperatingSegmentsMember 2019-06-01 2020-02-29 0000711377 us-gaap:IntersubsegmentEliminationsMember us-gaap:OperatingSegmentsMember 2019-06-01 2020-02-29 0000711377 neog:LiborPlusMember neog:UnsecuredRevolvingLineOfCreditMember 2019-06-01 2020-02-29 0000711377 us-gaap:OperatingSegmentsMember 2019-06-01 2020-02-29 0000711377 us-gaap:EmployeeStockMember neog:TwoThousandElevenPlanMember 2019-06-01 2020-02-29 0000711377 neog:FoodSafetyMember 2018-06-01 2019-02-28 0000711377 neog:AnimalSafetyMember 2018-06-01 2019-02-28 0000711377 neog:NaturalToxinsAllergensAndDrugResiduesMember neog:FoodSafetyMember 2018-06-01 2019-02-28 0000711377 neog:BacterialAndGeneralSanitationMember neog:FoodSafetyMember 2018-06-01 2019-02-28 0000711377 neog:CultureMediaAndOtherMember neog:FoodSafetyMember 2018-06-01 2019-02-28 0000711377 neog:RodenticidesInsecticidesAndDisinfectantsMember neog:FoodSafetyMember 2018-06-01 2019-02-28 0000711377 neog:GenomicsServicesMember neog:FoodSafetyMember 2018-06-01 2019-02-28 0000711377 neog:LifeSciencesMember neog:AnimalSafetyMember 2018-06-01 2019-02-28 0000711377 neog:VeterinaryInstrumentsAndDisposablesMember neog:AnimalSafetyMember 2018-06-01 2019-02-28 0000711377 neog:AnimalCareAndOtherMember neog:AnimalSafetyMember 2018-06-01 2019-02-28 0000711377 neog:RodenticidesInsecticidesAndDisinfectantsMember neog:AnimalSafetyMember 2018-06-01 2019-02-28 0000711377 neog:GenomicsServicesMember neog:AnimalSafetyMember 2018-06-01 2019-02-28 0000711377 us-gaap:NonUsMember 2018-06-01 2019-02-28 0000711377 country:US 2018-06-01 2019-02-28 0000711377 us-gaap:ProductMember neog:FoodSafetyMember us-gaap:OperatingSegmentsMember 2018-06-01 2019-02-28 0000711377 us-gaap:ProductMember neog:AnimalSafetyMember us-gaap:OperatingSegmentsMember 2018-06-01 2019-02-28 0000711377 us-gaap:ProductMember 2018-06-01 2019-02-28 0000711377 us-gaap:ServiceMember neog:FoodSafetyMember us-gaap:OperatingSegmentsMember 2018-06-01 2019-02-28 0000711377 us-gaap:ServiceMember neog:AnimalSafetyMember us-gaap:OperatingSegmentsMember 2018-06-01 2019-02-28 0000711377 us-gaap:ServiceMember 2018-06-01 2019-02-28 0000711377 neog:FoodSafetyMember us-gaap:OperatingSegmentsMember 2018-06-01 2019-02-28 0000711377 neog:AnimalSafetyMember us-gaap:OperatingSegmentsMember 2018-06-01 2019-02-28 0000711377 us-gaap:IntersubsegmentEliminationsMember us-gaap:OperatingSegmentsMember 2018-06-01 2019-02-28 0000711377 us-gaap:CommonStockMember 2018-06-01 2018-08-31 0000711377 us-gaap:AdditionalPaidInCapitalMember 2018-06-01 2018-08-31 0000711377 us-gaap:RetainedEarningsMember 2018-06-01 2018-08-31 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-01 2018-08-31 0000711377 us-gaap:CommonStockMember 2019-06-01 2019-08-31 0000711377 us-gaap:AdditionalPaidInCapitalMember 2019-06-01 2019-08-31 0000711377 us-gaap:RetainedEarningsMember 2019-06-01 2019-08-31 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-01 2019-08-31 0000711377 us-gaap:CommonStockMember 2019-09-01 2019-11-30 0000711377 us-gaap:AdditionalPaidInCapitalMember 2019-09-01 2019-11-30 0000711377 us-gaap:RetainedEarningsMember 2019-09-01 2019-11-30 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-01 2019-11-30 0000711377 us-gaap:CommonStockMember 2018-09-01 2018-11-30 0000711377 us-gaap:AdditionalPaidInCapitalMember 2018-09-01 2018-11-30 0000711377 us-gaap:RetainedEarningsMember 2018-09-01 2018-11-30 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-01 2018-11-30 0000711377 neog:ClarusLabsIncMember 2018-08-01 2018-08-01 0000711377 neog:ClarusLabsIncMember srt:MaximumMember 2018-08-01 2018-08-01 0000711377 neog:ClarusLabsIncMember srt:MinimumMember 2018-08-01 2018-08-01 0000711377 neog:ClarusLabsIncMember 2018-08-01 0000711377 neog:ClarusLabsIncMember 2019-02-01 2019-02-28 0000711377 neog:LivestockGeneticServicesLlcMember 2018-09-04 2018-09-04 0000711377 srt:MaximumMember neog:LivestockGeneticServicesLlcMember 2018-09-04 2018-09-04 0000711377 neog:LivestockGeneticServicesLlcMember srt:MinimumMember 2018-09-04 2018-09-04 0000711377 neog:LivestockGeneticServicesLlcMember 2018-09-04 0000711377 neog:LivestockGeneticServicesLlcMember 2019-09-01 2019-09-01 0000711377 neog:EdmontonAlbertabasedDeltaGenomicsCentreMember 2019-01-01 2019-01-01 0000711377 srt:MinimumMember neog:EdmontonAlbertabasedDeltaGenomicsCentreMember 2019-01-01 2019-01-01 0000711377 srt:MaximumMember neog:EdmontonAlbertabasedDeltaGenomicsCentreMember 2019-01-01 2019-01-01 0000711377 neog:EdmontonAlbertabasedDeltaGenomicsCentreMember 2019-01-01 0000711377 neog:ProductosQuimicosMagiarMember country:AR 2020-01-01 2020-01-01 0000711377 neog:ProductosQuimicosMagiarMember country:UY 2020-01-01 2020-01-01 0000711377 neog:ProductosQuimicosMagiarMember country:AR srt:MinimumMember 2020-01-01 2020-01-01 0000711377 neog:ProductosQuimicosMagiarMember country:AR srt:MaximumMember 2020-01-01 2020-01-01 0000711377 neog:ProductosQuimicosMagiarMember country:UY srt:MinimumMember 2020-01-01 2020-01-01 0000711377 neog:ProductosQuimicosMagiarMember country:UY srt:MaximumMember 2020-01-01 2020-01-01 0000711377 country:AR neog:ProductosQuimicosMagiarMember 2020-01-01 0000711377 neog:ProductosQuimicosMagiarMember country:UY 2020-01-01 0000711377 neog:DiessechemSrlMember country:IT 2020-01-09 2020-01-09 0000711377 neog:DiessechemSrlMember country:IT srt:MinimumMember 2020-01-09 2020-01-09 0000711377 neog:DiessechemSrlMember country:IT srt:MaximumMember 2020-01-09 2020-01-09 0000711377 neog:DiessechemSrlMember country:IT 2020-01-09 0000711377 neog:AbtekBiologicalsLimitedMember 2020-01-31 0000711377 neog:AbtekBiologicalsLimitedMember 2020-01-31 2020-01-31 0000711377 neog:AbtekBiologicalsLimitedMember srt:MinimumMember 2020-01-31 2020-01-31 0000711377 neog:AbtekBiologicalsLimitedMember srt:MaximumMember 2020-01-31 2020-01-31 0000711377 srt:ScenarioForecastMember 2020-05-31 0000711377 neog:FoodSafetyMember us-gaap:OperatingSegmentsMember 2019-02-28 0000711377 neog:AnimalSafetyMember us-gaap:OperatingSegmentsMember 2019-02-28 0000711377 us-gaap:IntersubsegmentEliminationsMember us-gaap:OperatingSegmentsMember 2019-02-28 0000711377 neog:CellBiosciencesMember country:AU 2020-02-28 2020-02-28 0000711377 neog:ChileBasedMagiarChilenaMember us-gaap:SubsequentEventMember 2020-03-26 2020-03-26 0000711377 neog:ChileBasedMagiarChilenaMember us-gaap:SubsequentEventMember 2020-03-26 0000711377 us-gaap:CommonStockMember 2020-02-29 0000711377 us-gaap:AdditionalPaidInCapitalMember 2020-02-29 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-02-29 0000711377 us-gaap:RetainedEarningsMember 2020-02-29 0000711377 us-gaap:CommonStockMember 2019-02-28 0000711377 us-gaap:AdditionalPaidInCapitalMember 2019-02-28 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-02-28 0000711377 us-gaap:RetainedEarningsMember 2019-02-28 0000711377 us-gaap:CommonStockMember 2018-05-31 0000711377 us-gaap:AdditionalPaidInCapitalMember 2018-05-31 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-05-31 0000711377 us-gaap:RetainedEarningsMember 2018-05-31 0000711377 us-gaap:CommonStockMember 2018-08-31 0000711377 us-gaap:AdditionalPaidInCapitalMember 2018-08-31 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-08-31 0000711377 us-gaap:RetainedEarningsMember 2018-08-31 0000711377 us-gaap:CommonStockMember 2019-05-31 0000711377 us-gaap:AdditionalPaidInCapitalMember 2019-05-31 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-05-31 0000711377 us-gaap:RetainedEarningsMember 2019-05-31 0000711377 us-gaap:CommonStockMember 2019-08-31 0000711377 us-gaap:AdditionalPaidInCapitalMember 2019-08-31 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-08-31 0000711377 us-gaap:RetainedEarningsMember 2019-08-31 0000711377 us-gaap:CommonStockMember 2019-11-30 0000711377 us-gaap:AdditionalPaidInCapitalMember 2019-11-30 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-11-30 0000711377 us-gaap:RetainedEarningsMember 2019-11-30 0000711377 us-gaap:CommonStockMember 2018-11-30 0000711377 us-gaap:AdditionalPaidInCapitalMember 2018-11-30 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-11-30 0000711377 us-gaap:RetainedEarningsMember 2018-11-30 iso4217:USD xbrli:shares xbrli:pure neog:Segment iso4217:USD xbrli:shares
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
10-Q
(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended February 29, 2020.
or

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from
to
Commission file number
0-17988
Neogen Corporation
(Exact name of registrant as specified in its charter)

Michigan |  | 38-2367843
(State or other jurisdiction of incorporation or organization) |  | (IRS Employer Identification Number)

620 Lesher Place
Lansing, Michigan 48912
(Address of principal executive offices, including zip code)
(517)
372-9200
(Registrant’s telephone number, including area code)
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:

Title of each Class |  | Trading Symbol(s) |  | Name of each exchange on which registered

N/A
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO
☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES
☒
NO
☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a
non-accelerated
filer (see definition of “accelerated filer and large accelerated filer” in Rule
12b-2
of the Exchange Act):

Large accelerated filer |  | ☒ |  | Accelerated filer |  | ☐
Non-accelerated filer |  | ☐ |  | Smaller Reporting Company |  | ☐
Emerging growth company |  | ☐ |  |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act): YES
☐
NO
☒
As of February 29, 2020 there were 52,910,832 shares of Common Stock outstanding.

Table of Contents
NEOGEN CORPORATION AND SUBSIDIARIES

|  |  |  | Page No. |
PART I. FINANCIAL INFORMATION |  |  |  |
Item 1. |  | Interim Consolidated Financial Statements (unaudited) |  |  | 2 |
|  | Consolidated Balance Sheets – February 29, 2020 and May 31, 2019 |  |  | 2 |
|  | Consolidated Statements of Income – Three and nine months ended February 29, 2020 and February 28, 2019 |  |  | 3 |
|  | Consolidated Statements of Comprehensive Income – Three and nine months ended February 29, 2020 and February 28, 2019 |  |  | 4 |
|  | Consolidated Statements of Equity – Three and nine months ended February 29, 2020 and February 28, 2019 |  |  | 5 |
|  | Consolidated Statements of Cash Flows – Nine months ended February 29, 2020 and February 28, 2019 |  |  | 6 |
|  | Notes to Interim Consolidated Financial Statements – February 29, 2020 |  |  | 7 |
Item 2. |  | Management’s Discussion and Analysis of Financial Condition and Results of Operations |  |  | 19 |
Item 3. |  | Quantitative and Qualitative Disclosures About Market Risk |  |  | 27 |
Item 4. |  | Controls and Procedures |  |  | 27 |
PART II. OTHER INFORMATION |  |  |  |
Item 1. |  | Legal Proceedings |  |  | 28 |
Item 1A. |  | Risk Factors |  |  | 28 |
Item 6. |  | Exhibits |  |  | 28 |
SIGNATURES |  |  | 29 |
|  | CEO Certification |  |  |  |
|  | CFO Certification |  |  |  |
|  | Section 906 Certification |  |  |  |

1

Table of Contents
PART I – FINANCIAL INFORMATION
Item 1. Interim Consolidated Financial Statements
Neogen Corporation and Subsidiaries
Consolidated Balance Sheets
(in thousands, except share and
per share amounts)

|  | February 29, 2020 |  |  | May 31, 2019 |
|  | Unaudited |  |  | Un a udited |
Assets |  |  |  |  |  |  |  |
Current Assets |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 50,774 |  |  | $ | 41,688 |
Marketable securities |  |  | 277,149 |  |  |  | 225,836 |
Accounts receivable, less allowance of $1,400 and $1,700 at February 29, 2020 and May 31, 2019, respectively |  |  | 80,692 |  |  |  | 82,582 |
Inventories |  |  | 89,244 |  |  |  | 85,992 |
Prepaid expenses and other current assets |  |  | 17,016 |  |  |  | 13,431 |
Total Current Assets |  |  | 514,875 |  |  |  | 449,529 |
Net Property and Equipment |  |  | 78,394 |  |  |  | 74,847 |
Other Assets |  |  |  |  |  |  |  |
Goodwill |  |  | 109,761 |  |  |  | 103,619 |
Other non-amortizable intangible assets |  |  | 15,425 |  |  |  | 15,649 |
Amortizable intangible and other assets, net of accumulated amortization of $43,397 and $40,835 at February 29, 2020 and May 31, 2019, respectively |  |  | 55,046 |  |  |  | 52,096 |
Total Assets |  | $ | 773,501 |  |  | $ | 695,740 |
Liabilities and Stockholders’ Equity |  |  |  |  |  |  |  |
Current Liabilities |  |  |  |  |  |  |  |
Accounts payable |  | $ | 18,994 |  |  | $ | 19,063 |
Accrued compensation |  |  | 5,596 |  |  |  | 7,085 |
Income taxes |  |  | 1,479 |  |  |  | 601 |
Other accruals |  |  | 13,066 |  |  |  | 11,502 |
Total Current Liabilities |  |  | 39,135 |  |  |  | 38,251 |
Deferred Income Taxes |  |  | 16,343 |  |  |  | 15,618 |
Other Non-Current Liabilities |  |  | 6,152 |  |  |  | 3,972 |
Total Liabilities |  |  | 61,630 |  |  |  | 57,841 |
Commitments and Contingencies (note 8) |  |  |  |  |  |  |  |
Equity |  |  |  |  |  |  |  |
Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding |  |  | — |  |  |  | — |
Common stock, $0.16 par value, 120,000,000 shares authorized, 52,910,832 and 52,216,589 shares issued and outstanding at February 29, 2020 and May 31, 2019, respectively |  |  | 8,466 |  |  |  | 8,355 |
Additional paid-in capital |  |  | 254,537 |  |  |  | 221,937 |
Accumulated other comprehensive loss |  |  | (13,507 | ) |  |  | (11,640 | )
Retained earnings |  |  | 462,375 |  |  |  | 419,247 |
Total Stockholders’ Equity |  |  | 711,871 |  |  |  | 637,899 |
Total Liabilities and Stockholders’ Equity |  | $ | 773,501 |  |  | $ | 695,740 |

See notes to interim consolidated financial statements.
2

Table of Contents
Neogen Corporation and Subsidiaries
Consolidated Statements of Income (unaudited)
(in thousands, except per share amounts)

|  | Three Months Ended |  |  | Nine Months Ended |
|  | February 29/28, |  |  | February 29/28, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product revenues |  | $ | 77,736 |  |  | $ | 77,375 |  |  | $ | 247,071 |  |  | $ | 249,897 |
Service revenues |  |  | 22,133 |  |  |  | 20,325 |  |  |  | 62,025 |  |  |  | 54,527 |
Total Revenues |  |  | 99,869 |  |  |  | 97,700 |  |  |  | 309,096 |  |  |  | 304,424 |
Cost of Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of product revenues |  |  | 41,068 |  |  |  | 41,902 |  |  |  | 128,658 |  |  |  | 132,157 |
Cost of service revenues |  |  | 13,471 |  |  |  | 11,170 |  |  |  | 35,888 |  |  |  | 30,877 |
Total Cost of Revenues |  |  | 54,539 |  |  |  | 53,072 |  |  |  | 164,546 |  |  |  | 163,034 |
Gross Margin |  |  | 45,330 |  |  |  | 44,628 |  |  |  | 144,550 |  |  |  | 141,390 |
Operating Expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  |  | 17,675 |  |  |  | 16,722 |  |  |  | 53,206 |  |  |  | 52,454 |
General and administrative |  |  | 10,789 |  |  |  | 10,018 |  |  |  | 32,473 |  |  |  | 30,337 |
Research and development |  |  | 3,823 |  |  |  | 3,249 |  |  |  | 11,292 |  |  |  | 9,235 |
Total Operating Expenses |  |  | 32,287 |  |  |  | 29,989 |  |  |  | 96,971 |  |  |  | 92,026 |
Operating Income |  |  | 13,043 |  |  |  | 14,639 |  |  |  | 47,579 |  |  |  | 49,364 |
Other Income (Expense) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 1,600 |  |  |  | 1,335 |  |  |  | 4,381 |  |  |  | 3,290 |
Other income (expense) |  |  | (393 | ) |  |  | 649 |  |  |  | (832 | ) |  |  | 807 |
Total Other Income |  |  | 1,207 |  |  |  | 1,984 |  |  |  | 3,549 |  |  |  | 4,097 |
Income Before Taxes |  |  | 14,250 |  |  |  | 16,623 |  |  |  | 51,128 |  |  |  | 53,461 |
Provision for Income Taxes |  |  | 2,050 |  |  |  | 3,550 |  |  |  | 8,000 |  |  |  | 9,100 |
Net Income |  | $ | 12,200 |  |  | $ | 13,073 |  |  | $ | 43,128 |  |  | $ | 44,361 |
Net Income Per Share |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.23 |  |  | $ | 0.25 |  |  | $ | 0.82 |  |  | $ | 0.86 |
Diluted |  | $ | 0.23 |  |  | $ | 0.25 |  |  | $ | 0.82 |  |  | $ | 0.85 |

See notes to interim consolidated financial statements.
3

Table of Contents
Neogen Corporation and Subsidiaries
Consolidated Statements of Comprehensive Income (unaudited)
(in thousands)

|  | Three Months Ended |  |  | Nine Months Ended |
|  | February 29/28, |  |  | February 29/28, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Net income |  | $ | 12,200 |  |  | $ | 13,073 |  |  | $ | 43,128 |  |  | $ | 44,361 |
Other comprehensive income (loss), net of tax: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
currency translation adjustments |  |  | (1,761 | ) |  |  | 3,105 |  |  |  | (2,452 | ) |  |  | 617 |
Other comprehensive income, net of tax: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
unrealized gain on marketable securities |  |  | 172 |  |  |  | — |  |  |  | 585 |  |  |  | — |
Total comprehensive income |  | $ | 10,611 |  |  | $ | 16,178 |  |  | $ | 41,261 |  |  | $ | 44,978 |

See notes to interim consolidated financial statements.
4

Table of Contents
Neogen Corporation and Subsidiaries
Consolidated Statements of
Equity (unaudited)
(in thousands)

|  |  |  |  |  |  |  |  |  |  | Accumulated |  |  |  |  |  |  |
|  |  |  |  |  |  |  | Additional |  |  | Other |  |  |  |  |  |  |
|  | Common Stock |  |  | Paid-in |  |  | Comprehensive |  |  | Retained |  |  |  |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Income (Loss) |  |  | Earnings |  |  | Total |
Balance at May 31, 2019 |  |  | 52,217 |  |  | $ | 8,355 |  |  | $ | 221,937 |  |  | $ | (11,640 | ) |  | $ | 419,247 |  |  | $ | 637,899 |
Issuance of shares under share-based compensation plan |  |  | 196 |  |  |  | 30 |  |  |  | 9,683 |  |  |  | — |  |  |  | — |  |  |  | 9,713 |
Issuance of shares under employee stock purchase plan |  |  | 10 |  |  |  | 2 |  |  |  | 536 |  |  |  | — |  |  |  | — |  |  |  | 538 |
Net income for the three months ended August 31, 2019 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 14,652 |  |  |  | 14,652 |
Other comprehensive loss for the three months ended August 31 , 2019 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (2,496 | ) |  |  | — |  |  |  | (2,496 | )
Balance at August 31, 2019 |  |  | 52,423 |  |  | $ | 8,387 |  |  | $ | 232,156 |  |  | $ | (14,136 | ) |  | $ | 433,899 |  |  | $ | 660,306 |
Issuance of shares under share-based compensation plan |  |  | 288 |  |  |  | 47 |  |  |  | 12,070 |  |  |  | — |  |  |  | — |  |  |  | 12,117 |
Net income for the three months ended November 30, 2019 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 16,276 |  |  |  | 16,276 |
Other comprehensive income for the three months ended November 30, 2019 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2,218 |  |  |  | — |  |  |  | 2,218 |
Balance at November 30, 2019 |  |  | 52,711 |  |  | $ | 8,434 |  |  | $ | 244,226 |  |  | $ | (11,918 | ) |  | $ | 450,175 |  |  | $ | 690,917 |
Issuance of shares under share-based compensation plan |  |  | 188 |  |  |  | 31 |  |  |  | 9,705 |  |  |  | — |  |  |  | — |  |  |  | 9,736 |
Issuance of shares under employee stock purchase plan |  |  | 12 |  |  |  | 1 |  |  |  | 606 |  |  |  | — |  |  |  | — |  |  |  | 607 |
Net income for the three months ended February 29, 2020 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 12,200 |  |  |  | 12,200 |
Other comprehensive loss for the three months ended February 29 , 2020 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,589 | ) |  |  | — |  |  |  | (1,589 | )
Balance at February 29, 2020 |  |  | 52,911 |  |  | $ | 8,466 |  |  | $ | 254,537 |  |  | $ | (13,507 | ) |  | $ | 462,375 |  |  | $ | 711,871 |

|  |  |  |  |  |  |  |  |  |  | Accumulated |  |  |  |  |  |  |
|  |  |  |  |  |  |  | Additional |  |  | Other |  |  |  |  |  |  |
|  | Common Stock |  |  | Paid-in |  |  | Comprehensive |  |  | Retained |  |  |  |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Income (Loss) |  |  | Earnings |  |  | Total |
Balance at May 31, 2018 |  |  | 51,736 |  |  | $ | 8,278 |  |  | $ | 202,572 |  |  | $ | (9,746 | ) |  | $ | 359,071 |  |  | $ | 560,175 |
Issuance of shares under share-based compensation plan |  |  | 251 |  |  |  | 40 |  |  |  | 8,433 |  |  |  | — |  |  |  | — |  |  |  | 8,473 |
Issuance of shares under employee stock purchase plan |  |  | 8 |  |  |  | 2 |  |  |  | 517 |  |  |  | — |  |  |  | — |  |  |  | 519 |
Net income for the three months ended August 31, 2018 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 15,237 |  |  |  | 15,237 |
Other comprehensive loss for the three months ended August 31, 2018 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (2,778 | ) |  |  | — |  |  |  | (2,778 | )
Balance at August 31, 2018 |  |  | 51,995 |  |  | $ | 8,320 |  |  | $ | 211,522 |  |  | $ | (12,524 | ) |  | $ | 374,308 |  |  | $ | 581,626 |
Issuance of shares under share-based compensation plan |  |  | 87 |  |  |  | 14 |  |  |  | 4,093 |  |  |  | — |  |  |  | — |  |  |  | 4,107 |
Net income for the three months ended November 30, 2018 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 16,051 |  |  |  | 16,051 |
Other comprehensive income for the three months ended November 30, 2018 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 290 |  |  |  | — |  |  |  | 290 |
Balance at November 30, 2018 |  |  | 52,082 |  |  | $ | 8,334 |  |  | $ | 215,615 |  |  | $ | (12,234 | ) |  | $ | 390,359 |  |  | $ | 602,074 |
Issuance of shares under share-based compensation plan |  |  | 78 |  |  |  | 12 |  |  |  | 4,146 |  |  |  | — |  |  |  | — |  |  |  | 4,158 |
Issuance of shares under employee stock purchase plan |  |  | 10 |  |  |  | 1 |  |  |  | 640 |  |  |  | — |  |  |  | — |  |  |  | 641 |
Shares repurchased |  |  | (50 | ) |  |  | (8 | ) |  |  | (3,127 | ) |  |  | — |  |  |  | — |  |  |  | (3,135 | )
Net income for the three months ended February 28, 2019 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 13,073 |  |  |  | 13,073 |
Other comprehensive loss for the three months ended February 28, 2019 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,105 |  |  |  | — |  |  |  | 3,105 |
Balance at February 28, 2019 |  |  | 52,120 |  |  | $ | 8,339 |  |  | $ | 217,274 |  |  | $ | (9,129 | ) |  | $ | 403,432 |  |  | $ | 619,916 |

See notes to interim consolidated financial statements.
5

Table of Contents
Neogen Corporation and Subsidiaries
Consolidated Statements of Cash Flows (unaudited)
(in thousands)

|  | Nine Months Ended February 29/28, |
|  | 2020 |  |  | 2019 |
Cash Flows From Operating Activities |  |  |  |  |  |  |  |
Net Income |  | $ | 43,128 |  |  | $ | 44,361 |
Adjustments to reconcile net income to net cash from operating activities: |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 13,542 |  |  |  | 13,028 |
Share-based compensation |  |  | 4,795 |  |  |  | 4,137 |
Change in operating assets and liabilities, net of business acquisitions: |  |  |  |  |  |  |  |
Accounts receivable |  |  | 3,841 |  |  |  | (898 | )
Inventories |  |  | (2,238 | ) |  |  | (8,745 | )
Prepaid expenses and other current assets |  |  | (3,119 | ) |  |  | (1,463 | )
Accounts payable, accruals and other changes |  |  | 301 |  |  |  | (7,455 | )
Net Cash From Operating Activities |  |  | 60,250 |  |  |  | 42,965 |
Cash Flows For Investing Activities |  |  |  |  |  |  |  |
Purchases of property, equipment and other assets |  |  | (16,322 | ) |  |  | (11,877 | )
Proceeds from the sale of marketable securities |  |  | 300,448 |  |  |  | 290,827 |
Purchases of marketable securities |  |  | (351,002 | ) |  |  | (316,195 | )
Business acquisitions, net of cash acquired |  |  | (9,701 | ) |  |  | (6,388 | )
Net Cash For Investing Activities |  |  | (76,577 | ) |  |  | (43,633 | )
Cash Flows From Financing Activities |  |  |  |  |  |  |  |
Exercise of stock options and issuance of employee stock purchase plan shares |  |  | 27,915 |  |  |  | 13,752 |
Repurchase of common stock |  |  | — |  |  |  | (3,135 | )
Net Cash From Financing Activities |  |  | 27,915 |  |  |  | 10,617 |
Effect of Exchange Rates on Cash |  |  | (2,502 | ) |  |  | 553 |
Net Increase In Cash and Cash Equivalents |  |  | 9,086 |  |  |  | 10,502 |
Cash and Cash Equivalents, Beginning of Period |  |  | 41,688 |  |  |  | 83,074 |
Cash and Cash Equivalents, End of Period |  | $ | 50,774 |  |  | $ | 93,576 |

See notes to interim consolidated financial statements.
6

Table of Contents
NEOGEN CORPORATION AND SUBSIDIARIES
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1. ACCOUNTING POLICIES
BASIS OF PRESENTATION AND CONSOLIDATION
The accompanying unaudited consolidated financial statements include the accounts of Neogen Corporation (“Neogen” or the “Company”) and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form
10-Q
and Article 10 of Regulation
S-X.
Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.
In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included in the accompanying unaudited consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. The results of operations for the three and nine month periods ended February 29, 2020 are not necessarily indicative of the results to be expected for the fiscal year ending May 31, 2020. For more complete financial information, these consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form
10-K
for the fiscal year ended May 31, 2019.
Recently Adopted Accounting Standards
Leases
On June 1, 2019, the Company adopted ASU No.
2016-02—
Leases. Refer to Leases section of Note 1 for further information.
Recent Accounting Pronouncements Not Yet Adopted
Financial Instruments - Credit Losses
In June 2016, the FASB issued ASU No.
2016-13—Measurement
of Credit Losses on Financial Instruments, which changes how companies measure credit losses on most financial instruments measured at amortized cost and certain other instruments, such as loans, receivables and
held-to-maturity
debt securities. Rather than generally recognizing credit losses when it is probable that the loss has been incurred, the revised guidance requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that the company expects to collect over the instrument’s contractual life. ASU
2016-13
is effective for fiscal periods beginning after December 15, 2019 and must be adopted as a cumulative effect adjustment to retained earnings. The Company does not believe adoption of this guidance will have a
material
impact on its consolidated financial statements.
Fair Value Measurements
In August 2018, the FASB issued ASU
2018-13—Fair
Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements of fair value measurements. ASU
2018-13
is effective for fiscal years beginning after December 15, 2019. The Company does not believe adoption of this guidance will have an impact on its consolidated financial statements.
Cloud Computing Implementation Cost
In August 2018, the FASB issued ASU
2018-15—Intangible-Goodwill
and Other
Internal-Use
Software (Subtopic
350-40):
Customer’s Accounting for Implementation Cost Incurred in a Cloud Computing Arrangement That Is a Service Contract, which clarifies the accounting for implementation costs in cloud computing arrangements. ASU
2018-15
is effective for fiscal years beginning after December 15, 2019. The Company does not believe adoption of this guidance will have an impact on its consolidated financial statements.
7

Table of Contents
Comprehensive Income
Comprehensive income represents net income and any revenues, expenses, gains and losses that, under U.S. generally accepted accounting principles, are excluded from net income and recognized directly as a component of equity. Accumulated other comprehensive income (loss) consists of foreign currency translation adjustments and unrealized gains or losses on marketable securities.
Fair Value of Financial Instruments
The carrying amounts of the Company’s financial instruments other than cash equivalents and marketable securities, which include accounts receivable and accounts payable, approximate fair value based on either their short maturity or current terms for similar instruments.
Fair value measurements are determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs. The Company utilizes a fair value hierarchy based upon the observability of inputs used in valuation techniques as follows:
Level 1: Observable inputs such as quoted prices in active markets;
Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
Cash and Cash Equivalents
Cash and cash equivalents consist of bank demand accounts, savings deposits, certificates of deposit and commercial paper with original maturities of 90 days or less. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and believes it is not exposed to significant credit risk regarding its cash and cash equivalents.
Marketable Securities
The Company has marketable securities held by banks or broker-dealers at February 29, 2020, consisting of short-term domestic certificates of deposit, and commercial paper and U.S. treasuries rated at least
A-1/P-1
(short-term) and A/A2 (long-term) with maturities between 91 days and two years. These securities are classified as available for sale. The primary objective of the Company’s investment activity is to preserve capital for the purpose of funding operations, capital expenditures and business acquisitions; investments are not entered into for trading or speculative purposes. These securities are recorded at fair value based on recent trades or pricing models and therefore meet the Level 2 criteria. Interest income on these investments is recorded within other income on the consolidated statements of income.
ESTIMATES AND ASSUMPTIONS
The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including, but not limited to, variable consideration related to revenue recognition, allowances for doubtful accounts, the market value of, and demand for, inventories, stock-based compensation, provision for income taxes and related balance sheet accounts, accruals, goodwill and other intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
There have been no significant changes to the critical accounting policies and estimates disclosed in the Company’s Annual Report on Form
10-K
for the fiscal year ended May 31, 2019.
There were no significant changes to the contractual obligations or contingent liabilities and commitments disclosed in the Company’s Annual Report on Form
10-K
for the fiscal year ended May 31, 2019.
8

Table of Contents
Accounts Receivable Allowance
Management attempts to minimize credit risk by reviewing customers’ credit history before extending credit and by monitoring credit exposure on a regular basis. An allowance for doubtful accounts is established based upon factors surrounding the credit risk of specific customers, historical trends and other information. Collateral or other security is generally not required for accounts receivable. Once a receivable balance has been determined to be uncollectible, that amount is charged against the allowance for doubtful accounts.
Inventory
The reserve for obsolete and slow-moving inventory is reviewed at least quarterly based on an analysis of the inventory, considering the current condition of the asset as well as other known facts and future plans. The reserve required to record inventory at lower of cost or net realizable value is adjusted as conditions change. Product obsolescence may be caused by shelf-life expiration, discontinuance of a product line, replacement products in the marketplace or other competitive situations.
Goodwill and Other Intangible Assets
Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses after amounts are allocated to other identifiable intangible assets. Other intangible assets include customer relationships, trademarks, licenses, trade names, covenants
not-to-compete
and patents. Customer-based intangibles are amortized on either an accelerated or straight-line basis, reflecting the pattern in which the economic benefits are consumed, while all other amortizable intangibles are amortized on a straight-line basis; intangibles are generally amortized over 5 to 25 years. We review the carrying amounts of goodwill and other
non-amortizable
intangible assets annually, or when indications of impairment exist, to determine if such assets may be impaired by performing a quantitative assessment. If the carrying amounts of these assets are deemed to be less than fair value based upon a discounted cash flow analysis and comparison to comparable EBITDA multiples of peer companies, such assets are reduced to their estimated fair value and a charge is recorded to operations.
Long-Lived Assets
Management reviews the carrying values of its long-lived assets to be held and used, including definite-lived intangible assets, for possible impairment whenever events or changes in business conditions warrant such a review. The carrying value of a long-lived asset is considered impaired when the anticipated separately identifiable undiscounted cash flows over the remaining useful life of the asset indicate that the carrying amount of the asset may not be recoverable. In such an event, fair value is determined using discounted cash flows and, if lower than the carrying value, impairment is recognized through a charge to operations.
Equity Compensation Plans
Share options awarded to employees and shares of stock awarded to employees under certain stock purchase plans are recognized as compensation expense based on their fair value at grant date. The fair market value of options granted under the Company stock option plans was estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for inputs such as interest rates, expected dividends, volatility measures and specific employee exercise behavior patterns based on statistical data. Some of the inputs used are not market-observable and have to be estimated or derived from available data. Use of different estimates would produce different option values, which in turn would result in higher or lower compensation expense recognized. To value options, several recognized valuation models exist. None of these models can be singled out as being the best or most correct. The model applied by us can handle most of the specific features included in the options granted, which is the reason for its use. If a different model were used, the option values could differ despite using the same inputs. Accordingly, using different assumptions coupled with using a different valuation model could have a significant impact on the fair value of employee stock options. Fair value could be either higher or lower than the number provided by the model applied and the inputs used. Further information on our equity compensation plans, including inputs used to determine the fair value of options, is disclosed in Note 5.
9

Table of Contents
Income Taxes
We account for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and for tax credit carryforwards and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax expense represents the change in net deferred income tax assets and liabilities during the year.
Leases
In February 2016, the FASB issued ASU No.
2016-02—Leases,
to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a
right-of-use
asset representing its right to use the underlying asset for the lease term. The recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessor have not significantly changed from previous U.S. GAAP. This ASU was effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2018. We adopted this ASU on June 1, 2019; the impact on our consolidated financial statements was immaterial.
We lease various manufacturing, laboratory, warehousing and distribution facilities, administrative and sales offices, equipment and vehicles under operating leases. We evaluate our contracts to determine if an arrangement is a lease at inception and classify it as a finance or operating lease. Currently, all our leases are classified as operating leases. Leased assets and corresponding liabilities are recognized based on the present value of the lease payments over the lease term. Our lease terms may include options to extend when it is reasonably certain that we will exercise that option.
Costs associated with operating leases are recognized on a straight-line basis within operating expenses over the term of the lease. With the adoption of ASC 842 on June 1, 2019, we recognized all leases with terms greater than 12 months in duration on our consolidated balance sheets as
right-of-use
assets and lease liabilities of approximately $2.0 million each as of June 1, 2019. We adopted the standard using the prospective approach and did not retrospectively apply to prior periods.
Right-of-use
assets are recorded in other assets on our consolidated balance sheets. Current and
non-current
lease liabilities are recorded in other accruals within current liabilities and other
non-current
liabilities, respectively, on our consolidated balance sheets.
We have made certain assumptions and judgments when applying ASC 842, the most significant of which are:

| • | We elected the package of practical expedients available for transition that allow us to not reassess whether expired or existing contracts contain leases under the new definition of a lease, lease classification for expired or existing leases and whether previously capitalized initial direct costs would qualify for capitalization under ASC 842.

| • | We did not elect to use hindsight when considering judgments and estimates such as assessments of lessee options to extend or terminate a lease or purchase the underlying asset.

| • | For all asset classes, we elected to not recognize a right-of-use asset and lease liability for short-term leases.

| • | For all asset classes, we elected to not separate non-lease components from lease components to which they relate and have accounted for the combined lease and non-lease components as a single lease component.

| • | The determination of the discount rate used in a lease is our incremental borrowing rate that is based on what we would normally pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.

Supplemental balance sheet information related to operating leases was as follows:

|  | February 29, 2020 |
|  | (in thousands) |
Right of use - assets |  | $ | 1,755 |
Lease liabilities - current |  |  | 325 |
Lease liabilities - non-current |  |  | 1,467 |

10

Table of Contents
The weighted average remaining lease term and weighted average discount rate were as follows:

|  | February 29, 2020 |
Weighted average remaining lease term |  |  | 2.4 years |
Weighted average discount rate |  |  | 3.5% |

Operating lease expenses are classified as cost of revenues or operating expenses on the consolidated statements of income. The components of lease expense were as follows:

|  | Three Months Ended February 29, 2020 |  |  | Nine Months Ended February 29, 2020 |
|  | (in thousands) |  |  | (in thousands) |
Operating leases |  | $ | 316 |  |  | $ | 889 |
Short term leases |  |  | 25 |  |  |  | 106 |
Total lease expense |  | $ | 341 |  |  | $ | 995 |

Cash paid for amounts included in the measurement of lease liabilities for operating leases included in cash flows from operations on the statement of cash flows were approximately $868,000 for the nine months ended February 29, 2020. There were no
non-cash
additions to
right-of-use
assets obtained from new operating lease liabilities for the nine months ended February 29, 2020.
Undiscounted minimum lease payments as of February 29, 2020 were as follows:

|  | Amount |
|  | (in thousands) |
Years ending May 31, |  |  |  |
2020 (1) |  | $ | 289 |
2021 |  |  | 915 |
2022 |  |  | 358 |
2023 |  |  | 168 |
2024 |  |  | 94 |
2025 and thereafter |  |  | 26 |
Total lease payments |  |  | 1,850 |
Less: imputed interest |  |  | 58 |
Total lease liabilities |  | $ | 1,792 |

(1) | Excluding the nine months ended February 29, 2020.

The aggregate amount of future minimum annual rental payments applicable to noncancelable leases as of May 31, 2019 were as follows:

|  | Future Minimum Lease Payments |
|  | (in thousands) |
Years ending May 31, |  |  |  |
2020 |  | $ | 1,112 |
2021 |  |  | 810 |
2022 |  |  | 297 |
2023 |  |  | 101 |
Thereafter |  |  | 0 |
|  | $ | 2,320 |

11

Table of Contents
Revenue Recognition
The Company determines the amount of revenue to be recognized through
application
of the following steps:

| • | Identification of the contract with a customer;

| • | Identification of the performance obligations in the contract;

| • | Determination of the transaction price;

| • | Allocation of the transaction price to the performance obligations in the contract; and

| • | Recognition of revenue when, or as, the Company satisfies the performance obligations.

Essentially all our revenue is generated through contracts with our customers. A performance obligation is a promise in a contract to transfer a product or service to a customer. We generally recognize revenue at a point in time when all our performance obligations under the terms of a contract are satisfied. Revenue is recognized upon transfer of control of promised products and services in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The collectability of consideration on the contract is reasonably assured before revenue is recognized. To the extent that customer payment has been received before all recognition criteria are met, these revenues are initially deferred in other accruals on the balance sheet and the revenue is recognized in the period that all recognition criteria have been met. In certain situations, we provide rebates, marketing support, credits or incentives to selected customers, which are accounted for as variable consideration when estimating the amount of revenue to recognize on a contract. Variable consideration reduces the amount of revenue that is recognized. These variable consideration estimates are updated at the end of each reporting period based on information currently available.
The performance obligations in our contracts are generally satisfied well within one year of the contract inception. In such cases, we have elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. We have elected to utilize the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred because the amortization period for the prepaid costs that would otherwise have been deferred and amortized is one year or less. The Company accounts for shipping and handling for products as a fulfillment activity when goods are shipped. Revenue is recognized net of any tax collected from customers; the taxes are subsequently remitted to governmental authorities. The Company’s terms and conditions of sale generally do not provide for returns of product or reperformance of service except in the case of quality or warranty issues. These situations are infrequent; due to immateriality of the amount, warranty claims are recorded in the period incurred.
We derive revenue from two primary sources - product revenue and service revenue.
Product revenue consists of shipments of:

| • | Diagnostic test kits, dehydrated culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation;

| • | Consumable products marketed to veterinarians and animal health product distributors; and

| • | Rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

Revenues for our products are recognized and invoiced when the product is shipped to the customer.
Service revenue consists primarily of:

| • | Genomic identification and related interpretive bioinformatic services; and

| • | Other commercial laboratory services.

Revenues for our genomics and commercial laboratory services are recognized and invoiced when the applicable laboratory service is performed and the results are conveyed to the customer.
Payment terms for products and services are generally 30 to 60 days; international terms may be longer.
12

Table of Contents
The following table presents disaggregated revenue by major product and service categories for the three and nine month periods ended February 29, 2020 and February 28, 2019:

|  | Three Months ended February 2 9 /2 8 , |  |  | Nine Months ended February 2 9 /2 8 , |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
|  | (in thousands) |
Food Safety |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Natural Toxins, Allergens & Drug Residues |  | $ | 17,154 |  |  | $ | 18,612 |  |  | $ | 57,950 |  |  | $ | 58,021 |
Bacterial & General Sanitation |  |  | 9,413 |  |  |  | 9,519 |  |  |  | 31,345 |  |  |  | 30,807 |
Culture Media & Other |  |  | 11,222 |  |  |  | 11,893 |  |  |  | 35,259 |  |  |  | 36,302 |
Rodenticides, Insecticides & Disinfectants |  |  | 7,964 |  |  |  | 5,953 |  |  |  | 20,859 |  |  |  | 18,521 |
Genomics Services |  |  | 4,745 |  |  |  | 5,136 |  |  |  | 12,961 |  |  |  | 13,395 |
|  | $ | 50,498 |  |  | $ | 51,113 |  |  | $ | 158,374 |  |  | $ | 157,046 |
Animal Safety |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Life Sciences |  | $ | 1,376 |  |  | $ | 1,823 |  |  | $ | 4,901 |  |  | $ | 5,794 |
Veterinary Instruments & Disposables |  |  | 10,799 |  |  |  | 10,682 |  |  |  | 32,621 |  |  |  | 32,769 |
Animal Care & Other |  |  | 6,667 |  |  |  | 6,554 |  |  |  | 20,859 |  |  |  | 21,900 |
Rodenticides, Insecticides & Disinfectants |  |  | 14,558 |  |  |  | 13,525 |  |  |  | 47,462 |  |  |  | 49,460 |
Genomics Services |  |  | 15,971 |  |  |  | 14,003 |  |  |  | 44,879 |  |  |  | 37,455 |
|  | $ | 49,371 |  |  | $ | 46,587 |  |  | $ | 150,722 |  |  | $ | 147,378 |
Total Revenues |  | $ | 99,869 |  |  | $ | 97,700 |  |  | $ | 309,096 |  |  | $ | 304,424 |

2. INVENTORIES
Inventories are stated at the lower of cost, determined by the
first-in,
first-out
method, or net realizable value. The components of inventories follow:

|  | February 29, |  |  | May 31, |
|  | 2020 |  |  | 2019 |
|  | (in thousands) |
Raw materials |  | $ | 42,243 |  |  | $ | 41,594 |
Work-in-process |  |  | 5,402 |  |  |  | 5,581 |
Finished and purchased goods |  |  | 41,599 |  |  |  | 38,817 |
|  | $ | 89,244 |  |  | $ | 85,992 |

3. NET INCOME PER SHARE
The calculation of net income per share follows:

|  | Three Months Ended |  |  | Nine Months Ended |
|  | February 29/28, |  |  | February 29/28, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
|  | (in thousands, except per share amounts) |
Numerator for basic and diluted net income per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net income attributable to Neogen |  | $ | 12,200 |  |  | $ | 13,073 |  |  | $ | 43,128 |  |  | $ | 44,361 |
Denominator for basic net income per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average shares |  |  | 52,795 |  |  |  | 52,071 |  |  |  | 52,463 |  |  |  | 51,849 |
Effect of dilutive stock options |  |  | 253 |  |  |  | 401 |  |  |  | 320 |  |  |  | 599 |
Denominator for diluted net income per share |  |  | 53,048 |  |  |  | 52,472 |  |  |  | 52,783 |  |  |  | 52,448 |
Net income attributable to Neogen per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.23 |  |  | $ | 0.25 |  |  | $ | 0.82 |  |  | $ | 0.86 |
Diluted |  | $ | 0.23 |  |  | $ | 0.25 |  |  | $ | 0.82 |  |  | $ | 0.85 |

13

Table of Contents
4. SEGMENT INFORMATION AND GEOGRAPHIC DATA
We have two reportable segments: Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits, dehydrated culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors; this segment also provides genomic identification and related interpretive bioinformatic services. Additionally, the Animal Safety segment produces and markets rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.
Our international operations in the United Kingdom, Mexico, Brazil, China and India originally focused on the Company’s food safety products, and each of these units reports through the Food Safety segment. In recent years, these operations have expanded to offer our complete line of products and services, including those usually associated with the Animal Safety segment such as cleaners, disinfectants, rodenticides, insecticides, veterinary instruments and genomics services. These additional products and services are managed and directed by existing management and are reported through the Food Safety segment.
The accounting policies of each of the segments are the same as those described in Note 1.
Segment information follows:

|  | Food Safety |  |  | Animal Safety |  |  | Corporate and Eliminations (1) |  |  | Total |
|  | (in thousands) |
As of and for the three months ended February 29, 2020 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product revenues to external customers |  | $ | 44,450 |  |  | $ | 33,286 |  |  | $ | — |  |  | $ | 77,736 |
Service revenues to external customers |  |  | 6,048 |  |  |  | 16,085 |  |  |  | — |  |  |  | 22,133 |
Total revenues to external customers |  |  | 50,498 |  |  |  | 49,371 |  |  |  | — |  |  |  | 99,869 |
Operating income (loss) |  |  | 5,881 |  |  |  | 8,492 |  |  |  | (1,330 | ) |  |  | 13,043 |
Total assets |  |  | 226,077 |  |  |  | 219,501 |  |  |  | 327,923 |  |  |  | 773,501 |
As of and for the three months ended February 28, 2019 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product revenues to external customers |  | $ | 44,790 |  |  | $ | 32,585 |  |  | $ | — |  |  | $ | 77,375 |
Service revenues to external customers |  |  | 6,323 |  |  |  | 14,002 |  |  |  | — |  |  |  | 20,325 |
Total revenues to external customers |  |  | 51,113 |  |  |  | 46,587 |  |  |  | — |  |  |  | 97,700 |
Operating income (loss) |  |  | 8,339 |  |  |  | 7,338 |  |  |  | (1,038 | ) |  |  | 14,639 |
Total assets |  |  | 204,570 |  |  |  | 221,335 |  |  |  | 246,680 |  |  |  | 672,585 |

(1) | Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities , current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions.

14

Table of Contents

|  | Food Safety |  |  | Animal Safety |  |  | Corporate and Eliminations (1) |  |  | Total |
|  | (in thousands) |
As of and for the nine months ended February 29, 2020 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product revenues to external customers |  | $ | 141,516 |  |  | $ | 105,555 |  |  | $ | — |  |  | $ | 247,071 |
Service revenues to external customers |  |  | 16,858 |  |  |  | 45,167 |  |  |  | — |  |  |  | 62,025 |
Total revenues to external customers |  |  | 158,374 |  |  |  | 150,722 |  |  |  | — |  |  |  | 309,096 |
Operating income (loss) |  |  | 24,571 |  |  |  | 26,521 |  |  |  | (3,513 | ) |  |  | 47,579 |
As of and for the nine months ended February 28, 2019 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product revenues to external customers |  | $ | 139,979 |  |  | $ | 109,918 |  |  | $ | — |  |  | $ | 249,897 |
Service revenues to external customers |  |  | 17,067 |  |  |  | 37,460 |  |  |  | — |  |  |  | 54,527 |
Total revenues to external customers |  |  | 157,046 |  |  |  | 147,378 |  |  |  | — |  |  |  | 304,424 |
Operating income (loss) |  |  | 29,554 |  |  |  | 23,101 |  |  |  | (3,291 | ) |  |  | 49,364 |

(1) | Includes elimination of intersegment transactions.

The following table presents the Company’s revenue disaggregated by geographic location:

|  | Three months ended |  |  | Nine months ended |
|  | February 29/28, |  |  | February 29/28, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
|  | (in thousands) |  |  | (in thousands) |
Revenues by Geographic Location |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Domestic |  | $ | 59,762 |  |  | $ | 57,422 |  |  | $ | 186,887 |  |  | $ | 182,298 |
International |  |  | 40,107 |  |  |  | 40,278 |  |  |  | 122,209 |  |  |  | 122,126 |
Total revenue |  |  | 99,869 |  |  |  | 97,700 |  |  |  | 309,096 |  |  |  | 304,424 |

15

Table of Contents
5. EQUITY COMPENSATION PLANS
Qualified and
non-qualified
options to purchase shares of common stock may be granted to directors, officers and employees of the Company under the terms of our stock option plans. These options are granted at an exercise price of not less than the fair market value of the stock on the date of grant. Options vest ratably over three and five year periods and the contractual terms are generally five or ten years. A summary of stock option activity during the nine months ended February 29, 2020 follows:

|  |  |  |  | Weighted- |
|  |  |  |  | Average |
(Options in thousands) |  | Shares |  |  | Exercise Price |
Options outstanding June 1, 2019 |  |  | 2,385 |  |  | $ | 49.37 |
Granted |  |  | 561 |  |  |  | 63.91 |
Exercised |  |  | (686 | ) |  |  | 40.07 |
Forfeited |  |  | (56 | ) |  |  | 56.67 |
Options outstanding February 29, 2020 |  |  | 2,204 |  |  | $ | 55.77 |

During the three and nine month periods ended February 29, 2020 and February 28, 2019, the Company recorded $1,640,000 and $1,306,000 and $4,795,000 and $4,137,000, respectively, of compensation expense related to its share-based awards.
The weighted-average fair value per share of stock options granted during the first nine months of fiscal 2020, estimated on the date of grant using the Black-Scholes option pricing model, was $15.56. The fair value of stock options granted was estimated using the following weighted-average assumptions.

|  | FY 2020 |
Risk-free interest rate |  |  | 1.9% |
Expected dividend yield |  |  | 0.0% |
Expected stock price volatility |  |  | 29.4% |
Expected option life |  |  | 3.5 years |

The Company has an employee stock purchase plan that provides for employee stock purchases at a 5% discount to market price. The discount is recorded in administrative expense as of the date of purchase.
6. BUSINESS AND PRODUCT LINE ACQUISITIONS
The Consolidated Statements of Income reflect the results of operations for business acquisitions since the respective dates of purchase. All are accounted for using the acquisition method. Goodwill recognized in the acquisitions discussed below relates primarily to enhancing the Company’s strategic platform for the expansion of available product offerings.
On August 1, 2018, the Company acquired the stock of Clarus Labs, Inc., a manufacturer of water testing products. Neogen has distributed Clarus’ Colitag water test to the food and beverage industries since 2004; this acquisition has given the Company the ability to sell this product to new markets. Consideration for the purchase was $4,204,000 in cash and approximately $1,256,000 of contingent consideration, due semiannually for the first five years, based on an excess net sales formula. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included inventory of $32,000, machinery and equipment of $120,000, accounts payable of $53,000, contingent consideration accrual of $1,256,000,
non-current
deferred tax liability of $544,000,
non-amortizable
intangible assets of $878,000, intangible assets of $1,487,000 (with an estimated life of
5-15
years) and the remainder to goodwill
(non-deductible
for tax purposes). These values are Level 3 fair value measurements. Since February 2019, $270,000 has been paid to the former owners as contingent consideration from the accrual. Manufacturing of these products was moved to the Company’s Lansing, Michigan location in October 2018, reporting within the Food Safety segment.
On September 4, 2018, the Company acquired the assets of Livestock Genetic Services, LLC, a Virginia-based company that specialized in genetic evaluations and data management for cattle breeding organizations. Livestock Genetic Services had been a long-time strategic partner of Neogen and the acquisition enhanced the Company’s
in-house
genetic evaluation capabilities. Consideration for the purchase was $1,100,000 in cash, with $700,000 paid at closing and $400,000 payable to the former owner on September 1, 2019, and up to $585,000 of contingent consideration, payable over the next three years. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included office equipment of $15,000, contingent consideration accrual of $385,000, intangible assets of $942,000 (with an estimated life of
5-15
years) and the remainder to goodwill (deductible to tax purposes). These values are Level 3 fair value measurements. In September 2019, the former owner was paid the
$400,000
installment of
the purchase
price owed
and was also paid $107,000 in contingent consideration based on the achievement of sales targets in the first year. Services provided by this operation are now performed at the Company’s Lincoln, Nebraska location, reporting within the Animal Safety segment.
16

Table of Contents
On January 1, 2019, the Company acquired the assets of Edmonton, Alberta based Delta Genomics Centre, an animal genomics laboratory in Canada. Delta’s laboratory operations were renamed Neogen Canada and the acquisition was intended to accelerate growth of the Company’s animal genomics business in Canada. Consideration for the purchase was $1,485,000 in cash. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included inventory of $38,000, machinery and equipment of $371,000, unearned revenue liability of $125,000, intangible assets of $532,000 (with an estimated life of 5 to 10 years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. Services provided by this operation continue to be performed in Edmonton, reporting within the Animal Safety segment.
On January 1, 2020, the Company acquired the stock of Productos Quimicos Magiar, a distributor of Neogen’s Food Safety products for the past 20 years, located in Argentina. Consideration for the purchase was $4,286,000 in net cash
,
with $3,786,000 paid at closing and $540,000 payable to the former owner on January 1, 2022, and up to $979,000 of contingent consideration, payable in one year, based upon an excess net sales formula.
The preliminary purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $603,000, inventory of $446,000, machinery and equipment of $36,000,
other current assets of
$221,000, accounts payable of $383,000, other current liabilities of $312,000
, contingent consideration accrual of $640,000
,
non-current
deferred tax liabilities of $
384,000
, intangible assets of $
1,282,000
(with an estimated life of
5-10
years) and the remainder to goodwill
(non-deductible
for tax purposes). These values are Level 3 fair value measurements. This operation continue
s
to operate from its current location in Buenos A
i
res, Argentina, reporting within the Food Safety segment. It
is
managed through
Neogen
’s Latin America operation.
On January 1, 2020, the Company acquired the stock of Productos Quimicos Magiar, a distributor of Neogen’s Food Safety products for the past 20 years, located in Uruguay. Consideration for the purchase was $1,596,000 in net cash
,
with $1,386,000 paid at closing and $210,000 payable to the former owner on January 1, 2022, and up to $241,000 in contingent consideration, payable in one year, based upon an excess net sales formula.
The preliminary purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $
280,000
, inventory of $
174,000
, machinery and equipment of $
16,000
,
other current assets
of $
68,000
, accounts payable of $
204,000
, other current liabilities of $
11,000
,
contingent consideration accrual of $159,000,
non-current
deferred tax liabilities of $
125,000
, intangible assets of $
498,000
(with an estimated life of
5-10
years) and the remainder to goodwill
(non-deductible
for tax purposes). These values are Level 3 fair value measurements. This operation continue
s
to operate from its current location in Montevideo, Uruguay, reporting within the Food Safety segment. It
is
managed through
Neogen
’s Latin America operation.
On January 9, 2020, the Company acquired the stock of Diessechem Srl, a distributor of food and feed diagnostics for the past 27 years, located in Italy. Consideration for the purchase was $3,455,000 in net cash. The preliminary purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $780,000, inventory of $5,000,
other curre
nt
assets
of $189,000, accounts payable of $140,000, other current liabilities of $334,000,
non-current
deferred tax liabilities of $203,000, intangible assets of $780,000 (with an estimated life of
5-10
years) and the remainder to goodwill
(non-deductible
for tax purposes). These values are Level 3 fair value measurements. This operation continue
s
to operate from its current location in Milan, Italy, reporting within the Food Safety segment. It
is
managed through Neogen’s Scotland operation.
On January 31, 2020, the Company acquired the stock of Abtek Biologicals Limited, a manufacturer and supplier of culture media supplements and microbiology technologies. This acquisition enhances the Company’s culture media product line offering for the worldwide industrial microbiology markets. Consideration for the purchase was $1,339,000
in net cash, with $1,220,000 paid at closing and $119,000 payable to the former owner on January 31, 2021.
The preliminary purchase price allocation, based upon
the fair
value of these assets and liabilities determined using the income approach, included accounts receivable of $
135,000
, inventory of $
207,000
, machinery and equipment of $
105,000
, prepayments of $
6,000
, accounts payable of $
118,000
, other current liabilities of $
34,000
,
non-current
deferred tax liabilities of $
101,000
, intangible assets of $
435,000
(with an estimated life of
5-10
years) and the remainder to goodwill
(non-deductible
for tax purposes). These values are Level 3 fair value measurements. This manufacturing operation will continue to operate from its current location in Liverpool, England, reporting within the Food Safety segment. It
is
managed through
Neogen
’s Scotland operation.
On February 28, 2020, the Company acquired the assets of Cell BioSciences, an Australian distributor of food safety and industrial microbiology products. This acquisition gives Neogen a direct sales presence across Australasia for its entire product portfolio. Consideration for the purchase was $3,443,000 in cash. Due to the timing of the transaction, the preliminary purchase price allocation was not complete at the time of filing. The business
is
operated under Neogen’s name in Melbourne, Australia, reporting within the Animal Safety segment.
Subsequent to the end of the quarter, on March 26, 2020, the Company acquired the assets of Chile-based Magiar Chilena, a distributor of food, animal, and plant diagnostics, including Neogen products. Consideration for the purchase was $400,000 in cash, with $350,000 paid at closing and $50,000 payable to the former owner on March 26, 2021. Due to the timing of the transaction, the preliminary purchase price allocation was not complete at the time of filing. The business will be operated from its current location in Santiago, Chile, reporting within the Food Safety segment. It will be managed through Neogen’s Latin America operation.
17

Table of Contents
7. LONG TERM DEBT
We have a financing agreement with a bank providing for a $15,000,000 unsecured revolving line of credit, which was amended on November 30, 2018 to extend the maturity from September 1, 2019 to September 30, 2021. There were no advances against the line of credit during fiscal 2019 and there have been none thus far in fiscal 2020; there was no balance outstanding at February 29, 2020. Interest on any borrowings
w
ill be charged
at LIBOR plus 100 basis points (rate under the terms of the agreement was 2.51% at February 29, 2020). Financial covenants include maintaining specified levels of tangible net worth, debt service coverage, and funded debt to EBITDA, each of which the Company was in compliance with at February 29, 2020.
8. COMMITMENTS AND CONTINGENCIES
The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for related costs when such costs are determined to be probable and estimable. The Company currently utilizes a pump and treat remediation strategy, which includes semi-annual monitoring and reporting, consulting, and maintenance of monitoring wells. Neogen expenses these annual costs of remediation, which have ranged from $38,000 to $131,000 per year over the past five years. The Company’s estimated liability for these costs was $916,000 at both February 29, 2020 and May 31, 2019, measured on an undiscounted basis over an estimated period of 15 years; $100,000 of the liability is recorded within current liabilities and the remainder is recorded within other
non-current
liabilities on the consolidated balance sheets. In fiscal 2019, the Company performed an updated Corrective Measures Study (CMS) on the site, per a request from the Wisconsin Department of Natural Resources (WDNR), and is currently in discussion with the WDNR regarding potential alternative remediation strategies going forward. The Company believes that the current pump and treat strategy is appropriate for the site. At this time, the outcome of the review in terms of approach and future costs is unknown, but a change in the current remediation strategy, depending on the alternative selected, could require an increase in the currently recorded liability, with an offsetting charge to operations in the period recorded.
The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, should not have a material effect on its future results of operations or financial position.
9. STOCK PURCHASE
In October 2018, the Company’s Board of Directors passed a resolution canceling the Company’s prior stock buyback program, which had been approved in December 2008, and authorized a new program to purchase, subject to market conditions, up to 3,000,000 shares of the Company’s common stock. In December 2018, the Company purchased 50,000 shares under the program in negotiated and open market transactions for a total price, including commissions, of $3,134,727. Shares acquired under the program have been retired.
18

Table of Contents
PART I – FINANCIAL INFORMATION

Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations

The information in this Management’s Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen does not provide forecasts of future financial performance. While management is optimistic about the Company’s long-term prospects, historical financial information may not be indicative of future financial results.
Safe Harbor and Forward-Looking Statements
Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Quarterly Report on Form 10-Q. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors, including competition, recruitment and dependence on key employees, impact of weather on agriculture and food production, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation, widespread outbreak of an illness, including the COVID-19 pandemic, and other risks detailed from time to time in the Company’s reports on file at the Securities and Exchange Commission, that could cause Neogen Corporation’s results to differ materially from those indicated by such forward-looking statements, including those detailed in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
In addition, any forward-looking statements represent management’s views only as of the day this Quarterly Report on Form
10-Q
was first filed with the Securities and Exchange Commission and should not be relied upon as representing management’s views as of any subsequent date. While management may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its views change.
19

Table of Contents
Executive Overview

| • | Consolidated revenues were $99.9 million in the third quarter of fiscal 2020, an increase of 2% compared to $97.7 million in the third quarter of fiscal 2019. Organic sales growth in the third quarter of fiscal 2020 was 1%. For the year to date period, consolidated revenues were $309.1 million, an increase of 2% compared to $304.4 million in the same period in the prior fiscal year. Organic sales rose 1% for the nine month period.

| • | Food Safety segment sales were $50.5 million in the third quarter of the current fiscal year, a decline of 1% compared to $51.1 million in the same period of the prior year. Organic sales declined 3% during the quarter; contributions from four acquisitions executed during the quarter totaled $990,000. For the year to date, Food Safety segment sales were $158.4 million, an increase of 1% compared to $157.0 million in the same period of the prior fiscal year; excluding acquisitions, sales were flat.

| • | Animal Safety segment sales were $49.4 million in the third quarter of fiscal 2020, an increase of 6% compared to $46.6 million in the third quarter of fiscal 2019. Organic sales in this segment also rose 6% in the third quarter, with only a minor contribution from the January 1, 2019 acquisition of Delta Genomics. For the year to date, Animal Safety segment sales were $150.7 million, an increase of 2% compared to $147.4 million in the same period a year ago. Year to date organic sales also increased 2%.

| • | International sales in the third quarter of fiscal 2020 were 40% of total sales compared to 41% of total sales in the third quarter of fiscal 2019. For each year to date period presented, international sales were 40% of total sales.

| • | Our effective tax rate in the third quarter was 14.4% compared to 21.4% in the prior year third quarter; the fiscal 2020 year to date effective tax rate was 15.6% compared to 17.0% for the same period a year ago.

| • | Net income for the quarter ended February 29, 2020 was $12.2 million, or $0.23 per diluted share, a decrease of 7% compared to $13.1 million, or $0.25 per share in the same period in the prior year. For the year to date, net income was $43.1 million, or $0.82 per share, a decrease of 3% compared to prior year to date net income of $44.4 million, or $0.85 per diluted share.

| • | Cash provided from operating activities in the first nine months of fiscal 2020 was $60.3 million, compared to $43.0 million in the same period of fiscal 2019.

20

Table of Contents
International sales were flat in both the third quarter of fiscal 2020 and for the year to date, each compared to the same respective periods in the prior year. The rate of growth in our international revenues in the current fiscal year has been adversely impacted by currency devaluations in a number of the countries in which we operate, lower sales of our drug residue test kits by our largest European distributor, and the loss of forensics business in Brazil. Revenue changes, denominated in both the U.S. dollar and as reported in the local currency, for the three and nine month periods of fiscal 2020 compared to the same respective periods in the prior year are as follows for each of our international locations:

|  | Three Months Ended February 29, 2020 |  |  | Nine Months Ended February 29, 2020 |
|  | Revenue |  |  | Revenue |  |  | Revenue |  |  | Revenue |
|  | % Increase/(Decrease) USD |  |  | % Increase/(Decrease) Local Currency |  |  | % Increase USD |  |  | % Increase Local Currency |
UK Companies |  |  | 5 | % |  |  | 4 | % |  |  | 3 | % |  |  | 5 | %
Brazilian Companies |  |  | (16 | )% |  |  | (6 | )% |  |  | (5 | )% |  |  | 1 | %
Neogen Latinoamerica |  |  | 15 | % |  |  | 11 | % |  |  | 8 | % |  |  | 7 | %
Neogen China |  |  | 37 | % |  |  | 41 | % |  |  | 20 | % |  |  | 24 | %
Neogen India |  |  | 18 | % |  |  | 19 | % |  |  | 11 | % |  |  | 11 | %
Neogen Canada |  |  | 75 | % |  |  | 73 | % |  |  | 135 | % |  |  | 135 | %
Neogen Australasia |  |  | 7 | % |  |  | 12 | % |  |  | 15 | % |  |  | 22 | %

Currency translations reduced comparative revenues by approximately $357,000 in the third quarter of fiscal 2020 compared to the same quarter a year ago, and by $2.5 million for the year to date compared to the same period last year, primarily due to the increased strength of the U.S. dollar relative to the British pound, the Brazilian real and the Australian dollar for each period. The Mexican peso and the British pound strengthened relative to the U.S. dollar during the third quarter of 2020.
The 5% increase in third quarter revenues at our Neogen Europe operations included a 24% increase in sales of cleaners, disinfectants and veterinary instruments, offset somewhat by a 9% decline in culture media products, due to orders delayed into the fourth quarter and lower demand; sales of our allergen test kits increased 7%. For the year to date period, overall sales increased 3%. Sales in Brazil declined 16% in the third quarter, primarily from the loss of forensics test kit business, due to a large commercial laboratory converting their testing protocol to a higher throughput method, and lower sales of genomics services due to a large sale in the prior year period which did not recur. Partially offsetting these declines was a large
non-recurring
sale of insecticides to a government agency. For the nine month period, sales at our Brazilian operations decreased 5% compared to the prior year. At Neogen Latinoamerica, sales increased 15% for the third quarter compared to the prior year, with strong sales of rodenticides in Mexico and broad based strength across the diagnostics business during the period; for the year to date, strong diagnostics test kit sales were somewhat offset by lower sales of cleaners and disinfectants. Robust sales of cleaners and disinfectants in China in the third quarter of fiscal 2020, due in part to the
COVID-19
pandemic, drove the 38% increase in revenue and offset lower sales of diagnostic test kit sales in the period; for the year to date, revenues increased 20% over the prior year.
Service revenue was $22.1 million in the third quarter of fiscal 2020, an increase of 9% over prior year third quarter revenues of $20.3 million, including a minor contribution from the January 1, 2019 acquisition of Delta Genomics. For the nine month period, service revenue was $62.0 million, an increase of 14% over prior year revenues of $54.5 million. Year to date service revenues were aided by the Delta Genomics acquisition and the September 2018 acquisition of Livestock Genetic Services. The growth in both the quarter and year to date periods was led by strong increases of genomic testing revenues to the domestic companion animal market, and to a lesser extent, increases in our global beef and dairy cattle markets.
21

Table of Contents
Revenues

|  | Three Months Ended February 29/28, |  |  |  |  |  |  |
|  | 2020 |  |  | 2019 |  |  | Increase/ (Decrease) |  |  | % |
|  |  |  |  | (in thousands) |  |  |  |  |  |  |
Food Safety |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Natural Toxins, Allergens & Drug Residues |  | $ | 17,154 |  |  | $ | 18,612 |  |  | $ | (1,458 | ) |  |  | (8 | )%
Bacterial & General Sanitation |  |  | 9,413 |  |  |  | 9,519 |  |  |  | (106 | ) |  |  | (1 | )%
Culture Media & Other |  |  | 11,222 |  |  |  | 11,893 |  |  |  | (671 | ) |  |  | (6 | )%
Rodenticides, Insecticides & Disinfectants |  |  | 7,964 |  |  |  | 5,953 |  |  |  | 2,011 |  |  |  | 34 | %
Genomics Services |  |  | 4,745 |  |  |  | 5,136 |  |  |  | (391 | ) |  |  | (8 | )%
|  | $ | 50,498 |  |  | $ | 51,113 |  |  | $ | (615 | ) |  |  | (1 | )%
Animal Safety |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Life Sciences |  | $ | 1,376 |  |  | $ | 1,823 |  |  | $ | (447 | ) |  |  | (25 | )%
Veterinary Instruments & Disposables |  |  | 10,799 |  |  |  | 10,682 |  |  |  | 117 |  |  |  | 1 | %
Animal Care & Other |  |  | 6,667 |  |  |  | 6,554 |  |  |  | 113 |  |  |  | 2 | %
Rodenticides, Insecticides & Disinfectants |  |  | 14,558 |  |  |  | 13,525 |  |  |  | 1,033 |  |  |  | 8 | %
Genomics Services |  |  | 15,971 |  |  |  | 14,003 |  |  |  | 1,968 |  |  |  | 14 | %
|  | $ | 49,371 |  |  | $ | 46,587 |  |  | $ | 2,784 |  |  |  | 6 | %
Total Revenues |  | $ | 99,869 |  |  | $ | 97,700 |  |  | $ | 2,169 |  |  |  | 2 | %

|  | Nine Months Ended February 29/28, |  |  |  |  |  |  |
|  | 2020 |  |  | 2019 |  |  | Increase/ (Decrease) |  |  | % |
|  |  |  |  | (in thousands) |  |  |  |  |  |  |
Food Safety |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Natural Toxins, Allergens & Drug Residues |  | $ | 57,950 |  |  | $ | 58,021 |  |  | $ | (71 | ) |  |  | 0 | %
Bacterial & General Sanitation |  |  | 31,345 |  |  |  | 30,807 |  |  |  | 538 |  |  |  | 2 | %
Culture Media & Other |  |  | 35,259 |  |  |  | 36,302 |  |  |  | (1,043 | ) |  |  | (3 | )%
Rodenticides, Insecticides & Disinfectants |  |  | 20,859 |  |  |  | 18,521 |  |  |  | 2,338 |  |  |  | 13 | %
Genomics Services |  |  | 12,961 |  |  |  | 13,395 |  |  |  | (434 | ) |  |  | (3 | )%
|  | $ | 158,374 |  |  | $ | 157,046 |  |  | $ | 1,328 |  |  |  | 1 | %
Animal Safety |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Life Sciences |  | $ | 4,901 |  |  | $ | 5,794 |  |  | $ | (893 | ) |  |  | (15 | )%
Veterinary Instruments & Disposables |  |  | 32,621 |  |  |  | 32,769 |  |  |  | (148 | ) |  |  | 0 | %
Animal Care & Other |  |  | 20,859 |  |  |  | 21,900 |  |  |  | (1,041 | ) |  |  | (5 | )%
Rodenticides, Insecticides & Disinfectants |  |  | 47,462 |  |  |  | 49,460 |  |  |  | (1,998 | ) |  |  | (4 | )%
Genomics Services |  |  | 44,879 |  |  |  | 37,455 |  |  |  | 7,424 |  |  |  | 20 | %
|  | $ | 150,722 |  |  | $ | 147,378 |  |  | $ | 3,344 |  |  |  | 2 | %
Total Revenues |  | $ | 309,096 |  |  | $ | 304,424 |  |  | $ | 4,672 |  |  |  | 2 | %

22

Table of Contents
Food Safety
Natural Toxins, Allergens & Drug Residues –
Sales in this category decreased 8% and were flat for the nine month period ended February 29, 2020, respectively, compared to the same periods in the prior year. In the third quarter, sales of drug residue test kits were down 47%, resulting from lower demand at our European distributor. Effective January 1, 2020, we have modified our contract with this distributor to eliminate their exclusive distribution of our dairy drug residue test kits and we have begun selling this product line directly to end customers through Neogen Europe. Partially offsetting this decrease, sales of our allergens product line and natural toxin test kit revenues both increased 4%. For the nine month period, sales of our allergens product line increased 8% and natural toxins test kit revenues increased 5%, while sales of drug residue test kits declined 29%.
Bacterial & General Sanitation –
Revenues in this category decreased 1% in the third quarter and increased 2% for the year to date, both compared to the same periods in the prior year. In the third quarter, sales of our AccuPoint sanitation monitoring product line increased 5% on higher sales of both equipment and related samplers; sales of test kits to detect pathogens decreased 7%, in part due to higher equipment sales in the prior year third quarter. Sales of products to detect spoilage organisms in processed foods decreased 3%, due to lack of availability of certain consumable vials because of manufacturing issues, which have since been resolved. For the year to date, sales of our AccuPoint product line increased 13% and pathogen test kit revenues increased 2%, while sales of products to detect spoilage organisms decreased 10%.
Culture Media & Other –
Sales in this category decreased 6% in the quarter ended February 29, 2020 compared to the third quarter in the prior year; for the nine month period, sales decreased 3%. Sales of Neogen Culture Media decreased 7% and were flat for the quarter and year to date periods, respectively. The decrease in the third quarter is primarily due to order timing and lower end market demand. This category also includes forensic test kits sold within Brazil, which decreased significantly in both the third quarter and for the year to date as a large customer moved to a higher throughput testing method. For both periods, this category also benefitted from lower rebate payments to a European distributor in the current fiscal year.
Rodenticides, Insecticides & Disinfectants –
Revenues in this category increased 34% in the third quarter of fiscal 2020 compared to the same period a year ago, primarily from strength of disinfectant products in China due to the
COVID-19
outbreak. The quarter was also aided by a large sale of rodenticides in Mexico and the final shipment of a
non-recurring
sale of insecticide products to a governmental agency in Nicaragua. For the year to date, sales in this category increased 8%.
Genomics Services –
Sales of genomics services sold through our international Food Safety operations decreased 8% for the three month period ended February 29, 2020; revenues decreased 3% for the nine month period. For each comparative period, the decrease was caused primarily by lower sample volumes in our Brazilian genomics operations, resulting from a large government order in the prior year which has not recurred in the current year. Currency also negatively impacted revenues in the current fiscal year as both the British pound and the Brazilian real have weakened relative to the U.S. dollar. The Company has sizable genomics revenues in the U.K. and in Brazil, where the pound and real, respectively, are the functional currencies.
Animal Safety
Life Sciences –
Sales in this category decreased 25% in the third quarter, compared to the same period in the prior year; for the year to date, the decrease in this product line is 15%. The prior year included sales to a commercial laboratory customer which did not recur in fiscal 2020. Additionally, sales of substrates and reagents declined significantly in the third quarter, the result of order timing from a large customer.
Veterinary Instruments & Disposables –
Revenues in this category increased 1% for the three month period ended February 29, 2020; for the year to date, sales were flat. For both the quarter and year to date periods, growth in marking and other disposable products was essentially offset by decreased sales of various types of needles, due to high inventory levels at our largest distributors.
Animal Care & Other –
Sales of these products increased 2% in the third quarter and decreased 5% for the year to date. In the third quarter, animal care revenues decreased 4% due to lower sales to our larger U.S. distributors while sales of disposable dairy supplies rose 5%. For the year to date period, animal care revenues were 4% lower than the prior year, while dairy supplies were 2% lower. Timing of adjustments to promotional programs with distributors, which are recorded as contra revenues within this category, also contributed to the year to date decline.
23

Table of Contents
Rodenticides, Insecticides & Disinfectants –
Revenues in this category increased 8% for the three month period ended February 29, 2020, but decreased 4% for the year to date period. For the quarter, rodenticide sales rose 26% on the success of retail marketing programs and insecticide sales were up 5%. These gains for the three month period were partially offset by a 1% decline in sales of cleaners and disinfectants. For the year to date, rodenticides were down 2%, insecticides were down 6%, and cleaners and disinfectants declined 5%.
Genomics Services –
Sales in this category increased 14% in the third quarter and 20% for the year to date period, both compared to the prior year; the September 2018 acquisition of Livestock Genetic Services and the January 2019 acquisition of Delta Genomics contributed a minor amount of the growth in this category. The growth in both the three and nine month periods was the result of significant volume increases to the companion animal market due to product uptake at a large customer and, to a lesser extent, continued growth in the beef and dairy cattle, and porcine markets.
Gross Margin
Gross margin was 45.4% in the third quarter of fiscal 2020 compared to 45.7% in the same quarter a year ago. The change in gross margin is due primarily to a change in product mix resulting from a higher proportion of sales from the Animal Safety segment, which have lower gross margins than products sold through the Food Safety segment. Gross margin for the nine month period ended February 29, 2020 was 46.8% compared to 46.4% in the same period of the prior year, primarily the result of higher gross margins within the Animal Safety segment resulting from a 250 basis point margin improvement in the domestic genomics service business, due to a significant increase in revenues in the companion animal testing business, which have higher gross margins than other services within this business.
Operating Expenses
Operating expenses were $32.3 million in the third quarter, compared to $30.0 million in the same quarter of the prior year, an increase of 8%. Sales and marketing expenses rose $953,000, or 6%, primarily due to personnel related expenses, and higher shipping, regulatory and product registration costs. General and administrative expense rose $771,000, or 8%, resulting from increases in stock based compensation expense, personnel costs, legal and professional fees resulting from acquisitions completed in the quarter, and depreciation related to investments in information technology. Research and development expense was $3.8 million in the third quarter, an increase of $574,000, or 18%, compared to the same period in the prior year. The increase is primarily the result of development spending and outside services relating to a number of new products, which are expected to be launched in late fiscal 2020 or early fiscal 2021.
Operating expenses for the nine month period ended February 29, 2020 were $97.0 million, an increase of $4.9 million, or 5%, compared to the prior year. Driving the increase were research and development spending increases of $2.1 million, or 22%, due primarily to new product development, and a $2.1 million, or 7%, increase in general and administrative expense. The increase in general and administrative expense was led by increased stock based compensation expense, higher legal and professional fees, and an increase in depreciation expense.
Operating Income
Operating income was $13.0 million in the third quarter of fiscal 2020, compared to $14.6 million in the same period of the prior year; year to date operating income was $47.6 million compared to $49.4 million in the prior year. Expressed as a percentage of sales, operating income was 13.1% for the third quarter and 15.4% for the year to date, compared to 15.0% and 16.2%, respectively, in the prior year. The decline in operating margin percentage for each period in the current fiscal year was primarily the result of operating expenses that increased more than the rate of revenue growth. Additionally, in the third quarter of fiscal 2020, the gross margin percentage declined by 30 basis points; for the year to date, the gross margin percentage has increased by 40 basis points.
24

Table of Contents
Other Income

|  | Three Months Ended |  |  | Nine Months Ended |
|  | February 29/28 |  |  | February 29/28 |
(dollars in thousands) |  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Interest income (net of expense) |  | $ | 1,600 |  |  | $ | 1,335 |  |  | $ | 4,381 |  |  | $ | 3,290 |
Foreign currency transactions |  |  | (420 | ) |  |  | 104 |  |  |  | (889 | ) |  |  | (354 | )
Royalty income |  |  | — |  |  |  | — |  |  |  | 1 |  |  |  | 60 |
Deoxi contingent consideration |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (9 | )
Quat-Chem contingent consideration |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 422 |
Other |  |  | 28 |  |  |  | 545 |  |  |  | 56 |  |  |  | 688 |
Total Other Income |  | $ | 1,208 |  |  | $ | 1,984 |  |  | $ | 3,549 |  |  | $ | 4,097 |

The increase in interest income in both the three and nine month periods of fiscal 2020 compared to the same periods a year ago was the result of higher cash and marketable securities balances. Other expense resulting from foreign currency transactions was primarily the result of changes in the value of foreign currencies relative to the U.S. dollar in countries in which we operate.
Income Tax Expense
Income tax expense in the third quarter of fiscal 2020 was $2.1 million, an effective tax rate of 14.4%, compared to $3.6 million, an effective tax rate of 21.4%, in the same period of the prior year. For the year to date, income tax expense was $8.0 million, an effective rate of 15.6%, in fiscal 2020 and $9.1 million, an effective rate of 17.0%, in fiscal 2019. For each period, the primary difference between the statutory rate of 21% and the effective rates recorded is the benefit resulting from the exercise of stock options; this benefit was $781,000 in the third quarter of fiscal 2020 compared to $291,000 in the third quarter of the prior year. For the year to date, the benefit was $2,754,000 in fiscal 2020 compared to $3,065,000 in fiscal 2019. For both periods in the current fiscal year, adjustments to research and development credits and other deductions related to the Tax Reform Act of 2017 resulted in lower effective income tax rates.
Net Income
Net income was $12.2 million in the third quarter of fiscal 2020, a 7% decrease compared to $13.1 million in the same period in the prior year. The change in earnings for this year’s third quarter was the result of lower pretax income, offset somewhat by the decrease in the effective tax rate. For the year to date, net income decreased 3% from $44.4 million to $43.1 million; for the nine month period, current year net income was also negatively impacted by lower pretax income, offset somewhat by a lower effective tax rate.
Financial Condition and Liquidity
The overall cash, cash equivalents and marketable securities position of Neogen was $327.9 million at February 29, 2020, compared to $267.5 million at May 31, 2019. Approximately $60.3 million was generated from operations during the first nine months of fiscal 2020. Net cash proceeds of $27.9 million were realized from the exercise of stock options and issuance of shares under our Employee Stock Purchase Plan during the first nine months of fiscal 2020. We spent $16.3 million for property, equipment and other
non-current
assets in the first nine months of fiscal 2020, and approximately $9.7 million on acquisitions during the same period.
Net accounts receivable balances were $80.7 million at February 29, 2020, a decrease of $1.9 million, compared to $82.6 million at May 31, 2019. Days sales outstanding, a measurement of the time it takes to collect receivables, were 66 days at February 29, 2020, compared to 61 days at May 31, 2019 and 68 days at February 28, 2019. All customer accounts are actively managed and no losses in excess of amounts reserved are currently expected; attention is being paid to the potential negative impact of COVID-19 on our customers’ ability to pay their bills.
25

Table of Contents
Net inventory balances were $89.2 million at February 29, 2020, an increase of $3.2 million compared to a May 31, 2019 balance of $86.0 million. We actively monitor our inventory levels and balance the need for adequate levels of product availability to minimize backorders with a desire to improve inventory turnover and efficiency levels. We have programs in place to improve our turnover in fiscal 2020; however, during the year we have increased inventory levels at our European operations to mitigate potential supply chain disruptions from a disorderly Brexit. Also, during the third quarter, in anticipation of possible supply disruptions due to the
COVID-19
pandemic, we reviewed our inventories of key raw materials and adjusted levels upward in some instances to ensure product availability.
Inflation and changing prices are not expected to have a material effect on operations, as management believes it will continue to be successful in offsetting increased input costs with price increases and/or cost efficiencies.
Management believes that our existing cash and marketable securities balances at February 29, 2020, along with available borrowings under our credit facility and cash expected to be generated from future operations, will be sufficient to fund activities for the foreseeable future. However, existing cash and borrowing capacity may not be sufficient to meet our cash requirements to commercialize products currently under development or execute our plans to acquire other organizations, technologies or products that fit within our mission statement. Accordingly, we may choose to issue equity securities or enter into other financing arrangements for a portion of our future financing needs.
The
COVID-19
pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets. An extended period of global supply chain and economic disruption could materially affect our business, results of operations, access to sources of liquidity and financial condition.
26

Table of Contents
PART I – FINANCIAL INFORMATION

Item 3. | Quantitative and Qualitative Disclosures About Market Risk

We have interest rate and foreign exchange rate risk exposure but no long-term fixed rate investments or borrowings. Our primary interest rate risk is due to potential fluctuations of interest rates for variable rate borrowings (no long-term borrowings at February 29, 2020) and short-term investments.
Foreign exchange risk exposure arises because we market and sell our products throughout the world. Revenues in certain foreign countries as well as certain expenses related to those revenues are transacted in currencies other than the U.S. dollar. Our operating results are exposed to changes in exchange rates between the U.S. dollar and the British pound sterling, the euro, the Brazilian real, the Mexican peso, the Chinese yuan, the Australian dollar, and to a lesser extent, the Indian rupee, the Canadian dollar, the Argentine peso and the Uruguayan peso. When the U.S. dollar weakens against foreign currencies, the dollar value of revenues denominated in foreign currencies increases. When the U.S. dollar strengthens, the opposite situation occurs. Additionally, previously recognized revenues in the course of collection can be affected positively or negatively by changes in exchange rates. The Company enters into forward contracts to help mitigate the economic impact of fluctuations in certain currency exchange rates. These contracts are adjusted to fair value through earnings.
Neogen has assets, liabilities and operations outside of the United States, located in Scotland, England, Italy, Brazil, Mexico, Argentina, Uruguay, China, India, Canada, and Australia where the functional currency is the British pound sterling, euro, Brazilian real, Mexican peso, Argentine peso, Uruguay peso, Chinese yuan, Indian rupee, Canadian dollar and the Australian dollar respectively, and also transacts business throughout Europe in the euro. The Company’s investments in foreign subsidiaries are considered to be long-term.
PART I – FINANCIAL INFORMATION

Item 4. | Controls and Procedures

Evaluation | of Disclosure Controls and Procedures

An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of February 29, 2020 was carried out under the supervision and with the participation of the Company’s management, including the President & Chief Executive Officer and the Vice President & Chief Financial Officer (“the Certifying Officers”). Based on the evaluation, the Certifying Officers concluded that the Company’s disclosure controls and procedures are effective.
Changes in Internal Controls over Financial Reporting
No changes in our control over financial reporting were identified as having occurred during the quarter ended February 29, 2020 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.
27

Table of Contents
PART II – OTHER INFORMATION

Item 1. | Legal Proceedings

The Company is subject to legal and other proceedings in the normal course of business. In the opinion of management, the outcomes of these matters are not expected to have a material effect on the Company’s future results of operations or financial position.

Item 1A. | Risk Factors

Other than the risk factors set forth below, there have been no material changes from the risk factors disclosed in our Annual Report on Form
10-K
for the fiscal year ended May 31, 2019.
The widespread outbreak of an illness or any other communicable disease, or any other public health crisis, could adversely affect our business, results of operations and financial condition.
We could be negatively impacted by the widespread outbreak of an illness or any other communicable disease, or any other public health crisis that results in economic and trade disruptions, including the disruption of global supply chains. In December 2019, an outbreak of a new strain of coronavirus
(“COVID-19”)
began in Wuhan, Hubei Province, China. In March 2020, the World Health Organization declared
COVID-19
a pandemic. The
COVID-19
pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets. The extent of the impact of the
COVID-19
pandemic on our operational and financial performance, including our ability to execute our business strategies and initiatives in the expected time frame, will depend on future developments, including the duration and spread of the pandemic and related restrictions on travel and transports, all of which are uncertain and cannot be predicted. An extended period of global supply chain and economic disruption could materially affect our business, results of operations, access to sources of liquidity and financial condition.

Item 6. | Exhibits

(a) Exhibit Index

| 3 |  |  | Articles of Incorporation, as restated (incorporated by reference to Exhibit 3 to the registrant’s Form 10-Q filed on December 28, 2018)
| 10 |  |  | Amended and Restated Credit Agreement dated as of November 30, 2018 between Registrant and JP Morgan Chase N.A. (incorporated by reference to Exhibit 10.A of the registrant’s Form 8-K filed on December 6, 2018)
| 31.1 |  |  | Certification of Chief Executive Officer pursuant to Rule 13a-14(a).
| 31.2 |  |  | Certification of Chief Financial Officer pursuant to Rule 13a-14(a).
| 32 |  |  | Certification pursuant to 18 U.S.C. section 1350
| 101.INS |  |  | Inline XBRL Instance Document
| 101.SCH |  |  | Inline XBRL Taxonomy Extension Schema Document
| 101.CAL |  |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document
| 101.DEF |  |  | Inline XBRL Taxonomy Extension Definition Document
| 101.LAB |  |  | Inline XBRL Taxonomy Extension Label Linkbase Document
| 101.PRE |  |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document
| EX-104 |  |  | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

Items 2, 3, 4, and 5 are not applicable or removed or reserved and have been omitted.
28

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  |  |  |  |  | NEOGEN CORPORATION
|  |  |  |  |  | (Registrant)
Dated: April 3, 2020 |  |  |  |  |  |
|  |  |  |  |  | /s/ John E. Adent
|  |  |  |  |  | John E. Adent
|  |  |  |  |  | President & Chief Executive Officer
|  |  |  |  |  | (Principal Executive Officer)
Dated: April 3, 2020 |  |  |  |  |  |
|  |  |  |  |  | /s/ Steven J. Quinlan
|  |  |  |  |  | Steven J. Quinlan
|  |  |  |  |  | Vice President & Chief Financial Officer
|  |  |  |  |  | (Principal Financial Officer and Principal Accounting Officer)

29